Does IBRUTINIB Cause Second primary malignancy? 43 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 43 reports of Second primary malignancy have been filed in association with IBRUTINIB (Imbruvica). This represents 0.1% of all adverse event reports for IBRUTINIB.
43
Reports of Second primary malignancy with IBRUTINIB
0.1%
of all IBRUTINIB reports
18
Deaths
3
Hospitalizations
How Dangerous Is Second primary malignancy From IBRUTINIB?
Of the 43 reports, 18 (41.9%) resulted in death, 3 (7.0%) required hospitalization, and 4 (9.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IBRUTINIB. However, 43 reports have been filed with the FAERS database.
What Other Side Effects Does IBRUTINIB Cause?
Death (8,007)
Off label use (5,446)
Fatigue (4,479)
Diarrhoea (3,903)
Atrial fibrillation (3,671)
Pneumonia (3,015)
Incorrect dose administered (2,752)
Contusion (2,712)
Fall (2,375)
Asthenia (2,200)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which IBRUTINIB Alternatives Have Lower Second primary malignancy Risk?
IBRUTINIB vs IBUPROFEN
IBRUTINIB vs IBUPROFEN LYSINE
IBRUTINIB vs IBUPROFEN UNKNOWN PRODUCT
IBRUTINIB vs IBUPROFEN\IBUPROFEN
IBRUTINIB vs IBUPROFEN\PHENYLEPHRINE